Risk Of Knee Osteoarthritis Progression May Be Reduced By Use Of A Cane
A common, incurable joint disease, osteoarthritis (OA) is the leading cause of disability in elderly people. While nearly any joint can be affected, OA most often strikes the knee, particularly the inner aspect of the tibiofemoral joint. One source of stress on this vulnerable joint compartment is the knee adduction moment, an indication of weight placement while walking.
Actemra Inhibits Joint Damage And Improves Physical Function Of Patients With Rheumatoid Arthritis
Roche announced that Actemra (tocilizumab) can significantly inhibit structural damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment. Actemra also improved the patients' physical function after one year of therapy, leading to a better quality of life.
Trubion Announces Initiation Of Phase 2b Study Of TRU 015 For The Treatment Of Rheumatoid Arthritis
Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) announced that its partner, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has commenced patient dosing in the next Phase 2b clinical trial of TRU-015 in patients with rheumatoid arthritis (RA). In collaboration with Trubion, Wyeth Pharmaceuticals is developing TRU-015, SBI-087 and other CD20-directed products.
Dose Escalation With Enbrel R Is Significantly Lower Than Other Commonly Used Anti-TNF Agents In Patients With Rheumatoid Arthritis, DART Study, UK
New pan-European data presented at the British Society of Rheumatology's annual meeting in Liverpool demonstrate that patients treated with Enbrel (etanercept) required significantly lower dose escalation than patients treated with infliximab and adalimumab in the first 12 months of therapy.
A Bit Of Reassurance On Lyme Disease
Tick bites generate fears of Lyme disease in every parent, but this study of 99 children finds that one of Lyme's complications -- arthritis -- has a good prognosis. Researchers led by Robert Sundel, MD, a rheumatologist at Children's, found that 77 percent of children were cured with less than 3 months of antibiotic treatment.
Best Foot Forward? ... Not For People With Arthritis, UK
Painful foot problems suffered by people with arthritis are seriously neglected and are subject to huge and unacceptable regional variations, according to a team of foot care experts. Only a quarter of patients who need foot health care have adequate access to NHS services, and only half of all hospital rheumatology departments in the UK are able to access adequate basic foot care services for their patients.
NICE And Its Decision Not To Approve Rheumatoid Arthritis Drug Abatacept, UK
The failure of the UK National Institute for Clinical Excellence (NICE) to approve treatment of the rheumatoid arthritis (RA) drug abatacept on the National Health Service (NHS) is discussed in the lead Editorial in this week's Lancet. Abatacept, is, with rituximab and tocilizumab, one of three new drug classes that have shown clinically significant improvement for the treatment for RA.
Smart Instrument For Tissue Damage Assessment Developed By QUT Researchers
A tool with the potential to determine the level of tissue damage in patients with osteo-arthritis, sports injuries and other conditions affecting bone and cartilage is being developed by QUT researchersProfessor Oloyede said that the device, which he calls a "smarthroscope", may be able to reduce the cost of surgery, eliminate unnecessary surgery, and could be useful in developing countries.
Better Treatment For Autoimmune Diseases Could Result From Sugar Linkage
Researchers at the University of New Hampshire Glycomics Center have helped identify a specific carbohydrate structure that confers anti-inflammatory activity to a glycoprotein antibody that could lead to improved treatment of autoimmune diseases like lupus or rheumatoid arthritis.
Trubion Announces Initiation Of Phase 1 Study Of SBI-087 For The Treatment Of Rheumatoid Arthritis
Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) announced that its collaboration partner Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has initiated a Phase 1 clinical trial of SBI-087, a next-generation drug candidate for the treatment of rheumatoid arthritis (RA).